CHMP recommends Azarga for approval
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on recommendation for approval to grant a marketing authorisation for Alcon Laboratories’ Azarga 10 mg/ml / 5 mg/ml Eye drops. The suspension will be a more effective treatment of elevated intraocular pressure for adult patients suffering from ocular hypertension or open-angle glaucoma who have not benefited much from mono-therapy.The drug is a fixed combination of Timolol and Brinzolamide. These compounds reduce the production of aqueous humor by inhibiting the conversion of CO2 to bicarbonate in the eye’s ciliary body, hence controlling IOP.
- FDA Recommends Approval for Ophthalmic Product Enabled By InSite’s DuraSite® Technology
- FDC receives FDA approval for Timolol Maleate Ophthalmic Solution
- Bausch & Lomb’s pink eye drug likely to get FDA recommendation
- Akorn Announces FDA Approval Of Ciprofloxacin HCl Ophthalmic Solution USP, 0.3%
